MIR660

Summary

MIR660 (microRNA 660, HGNC:32916) is a microRNA gene on chromosome Xp11.23.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 724030 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32916
Approved symbol	MIR660
Name	microRNA 660
Location	Xp11.23
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-660
Ensembl gene	ENSG00000207970
Ensembl biotype	miRNA
Entrez	724030
RNAcentral	URS000075D69B — miRNA, 97 nt, 6 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000385235

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000385235 — 1 exons

Exon	Start	End
ENSE00001500241	50013241	50013337

Expression profiles

Bgee: expression breadth broad, 23 present calls, max score 77.43.

Top tissues by expression

23 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
heart	UBERON:0000948	77.43	gold quality
gastrocnemius	UBERON:0001388	75.16	gold quality
right atrium auricular region	UBERON:0006631	73.26	gold quality
monocyte	CL:0000576	72.34	gold quality
body of pancreas	UBERON:0001150	70.99	gold quality
ascending aorta	UBERON:0001496	70.82	gold quality
tibial nerve	UBERON:0001323	70.23	gold quality
lower esophagus muscularis layer	UBERON:0035833	69.92	gold quality
substantia nigra	UBERON:0002038	69.80	gold quality
colon	UBERON:0001155	69.03	gold quality
omental fat pad	UBERON:0010414	66.19	gold quality
left adrenal gland cortex	UBERON:0035825	65.68	gold quality
ectocervix	UBERON:0012249	65.66	gold quality
body of stomach	UBERON:0001161	65.59	gold quality
ovary	UBERON:0000992	64.58	gold quality
left ovary	UBERON:0002119	64.58	gold quality
thoracic mammary gland	UBERON:0005200	63.96	gold quality
endocervix	UBERON:0000458	63.84	gold quality
skin of abdomen	UBERON:0001416	62.92	gold quality
spleen	UBERON:0002106	61.99	gold quality
lung	UBERON:0002048	60.01	gold quality
left testis	UBERON:0004533	52.79	gold quality
right frontal lobe	UBERON:0002810	50.60	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.55

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 26)

• Mir-660 inhibits lung tumorigenesis by targeting MDM2-p53 interaction. (PMID:25501825)
• Results show that differential methylation between sexes is associated with altered levels of microRNAs miR-660 and miR-532 and related target genes. (PMID:25517766)
• Results indicate that the combination of miR-652 + miR-660 and Cyfra21-1 has the potential to help in the diagnosis of non-small cell lung carcinoma. (PMID:26213369)
• Importantly we report for the first time two new candidate miRNAs (miR-574-3p and miR-660-5p) as promising prognostic markers (PMID:26416693)
• Data show that four cardiac fibroblast-derived microRNAS miR-660-3p, miR-665, miR-1285-3p and miR-4491 were found significantly upregulated in heart and plasma during heart failure. (PMID:26683101)
• mir-486-5p is positively regulated by mir-660-5p in lung cancer cell lines, through the mir-660-MDM2-p53 pathway. (PMID:28124991)
• Data show that miroRNA miR-660-5p can regulate the proliferation, migration, and invasion of breast cancer cells, and is a potential therapeutic target for the clinical treatment of breast cancer. (PMID:28252173)
• This work unraveled three mRNA/miRNA networks (miR-29a-3p/TET2, miR-660-5p/EPAS1 and miR-494-3p/c-MYC) capable of affecting TKI-sensitivity in CML cells, thus leading to the design of novel targeted therapies aimed at eliminating TKI-resistant LSCs. (PMID:28533480)
• rescue experiments demonstrated that FOXO1 knockdown abolished the effects of miR660 knockdown on osteosarcoma (OS)cell proliferation and invasion. These results suggest that miR660 may serve oncogenic roles in OS by directly targeting FOXO1. Targeting miR660 may be an effective candidate for the treatment of patients with OS. (PMID:29901128)
• miR-660, as a tumor-suppressive gene, was significantly decreased in gastric cancer and directly bound to oncogene E2F3 to inhibit E2F3 expression. (PMID:30914234)
• Our current study suggests that miR-660-5p may control Non-small cell lung cancer (NSCLC) proliferation, viability, and metastasis by targeting KLF9, which provides a potential therapeutic target for NSCLC. (PMID:31128012)
• circFBXL5 promotes breast cancer progression by sponging miR-660. (PMID:31729134)
• Knockdown of miR-660 protects nucleus pulposus cells from TNF-a-induced apoptosis by targeting serum amyloid A1. (PMID:31907065)
• hsa_circ_0004018 suppresses the progression of liver fibrosis through regulating the hsa-miR-660-3p/TEP1 axis. (PMID:32584784)
• MiR-660-5p promotes the progression of hepatocellular carcinoma by interaction with YWHAH via PI3K/Akt signaling pathway. (PMID:32807493)
• miR-660-5p promotes breast cancer progression through down-regulating TET2 and activating PI3K/AKT/mTOR signaling. (PMID:33146288)
• Circ_0008305-mediated miR-660/BAG5 axis contributes to hepatocellular carcinoma tumorigenesis. (PMID:33481351)
• Circulating status of microRNAs 660-5p and 210-3p in breast cancer patients. (PMID:33533518)
• Circulating miR-660-5p is associated with no-reflow phenomenon in patients with ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. (PMID:33960307)
• Circ_SEC61A1 contributes to the progression of multiple myeloma cells via regulating miR-660-5p/CDK6 axis. (PMID:35030455)
• Tumor-promoting mechanisms of macrophage-derived extracellular vesicles-enclosed microRNA-660 in breast cancer progression. (PMID:35084622)
• circITCH suppresses cell proliferation and metastasis through miR-660/TFCP2 pathway in melanoma. (PMID:35274492)
• The role of differentially expressed miR-660 in peripheral blood lymphocytes of patients with pulmonary tuberculosis. (PMID:37000536)
• microRNA-660 Enhances Cisplatin Sensitivity via Decreasing SATB2 Expression in Lung Adenocarcinoma. (PMID:37107669)
• Decreased KLF3 Expression via miR-660-5p Targeting Suppresses Gastric Cancer Cell Progression. (PMID:37945021)
• miRNA-660-3p inhibits malignancy in glioblastoma via negative regulation of APOC1-TGFbeta2 signaling pathway. (PMID:37981873)

Cross-species orthologs

0 orthologs

Paralogs (2): MIR532 (ENSG00000207758), MIR188 (ENSG00000207768)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.